China Resources Zizhu possède des médicaments et des instruments de santé procréative, des médicaments oraux, des médicaments ophtalmiques, des médicaments contre le diabète, des médicaments d'anesthésie locale, des API et d'autres lignes de produits. Sur le marché national, les contraceptifs d'urgence (comprimés de lévonorgestrel) et les médicaments contre les grossesses précoces (comprimés de mifépristone) détiennent la plus grande part de marché, et les comprimés de lévonorgestrel sont la marque dominante dans la vente de médicaments sur la plateforme de commerce électronique O2O ces dernières années. Sur le marché international, China Resources Zizhu a obtenu la certification PQ de l'OMS et la certification BPF de l'OMS et des PIC. Elle est un fournisseur de médicaments pour la santé procréative des Nations Unies et de diverses grandes organisations internationales. La part de marché des exportations chinoises d'API de lévonorgestrel est la plus importante, et les exportations de comprimés de mifépristone et de misoprostol sont parmi les plus importantes de Chine. China Resources Zizhu soutient toujours le principe de l'entreprise "Une Chine saine, une bonne vie", en augmentant continuellement les investissements en R & D, en se concentrant sur l'innovation scientifique et technologique, avec l'attitude professionnelle et l'ingéniosité de la recherche de l'excellence dans le domaine de la santé procréative, des spécialités et des affaires internationales, en s'efforçant d'ouvrir un nouveau chapitre de développement.
1969
Establishment
In the 1960s and 1970s, Beijing No.3 Pharmaceutical Factory, the predecessor of the company initiated the development of 18-methylnorgestrel, a critical API used for contraceptives and became the first national approved manufacturer of this API a year later. The success of this project filled the gap of oral contraceptive API in China, had epoch-making significance, opened a new chapter for China's industry, and won the "National Science Congress Award" in March 1978.
1996
Relocation
To meet the requirements of urban planning, the manufacture site is relocated to current address, No. 27 Chaoyang North Road, Chaoyang District, Beijing, China. The production in the new manufacture site started on 1 March 1996.
2000
Restructuring
Beijing No. 3 Pharmaceutical Factory was restructured into Beijing Zizhu Pharmaceutical Company Limited in 2000, entering a new stage. The restructuring was in accordance with the State Council's policy on debt-to-equity conversion of partial state-owned enterprises, and approved by the State Economic and Trade Commission and the Beijing Municipal Economic Commission.
2008
API production base
The API production base in Qinhuangdao was built in 2008 based on international development strategical need and Beijing industrial development plan, which guarantees the reliability of API sources for company’s finished products.
2013
Joining CR
The company officially changed its name to China Resources Zizhu Pharmaceutical Co., Ltd. and has become a wholly owned subsidiary of China Resources Pharmaceutical Group since then, entering a brand new stage of development.
2015
Takeover of United Pharmaceutical
Beijing United Pharmaceutical completed the resumption of production and related GMP certification under CRZP’s guidance. The Class II new drug Epalrestat API and finished product were successfully marketed, becoming a billion-dollar variety for CRZP and injecting new momentum into the specialty area.
2021
Green Factory Award
CRZP was selected as a National Green Factory during the event organized by the Ministry of Industry and Information Technology, aiming at implementing "Made in China 2025" and "Industrial Green Development Plan", accelerating the construction of green manufacturing system and creating advanced models of green manufacturing enterprises.
2022
Current
Committing to human life and health industry, CRZP develops, manufactures and markets pharmaceuticals and health products revolving around female health, characteristic specialties, APIs and international business.
2019.11
2019.11
WHO GMP
Co-package of Mifepristone Tablets and Misoprostol Tablets
2018.12
2018.12
EU GMP
Levonorgestrel API
2018.10
2018.10
EDQM GMP
Levonorgestrel API
2016.10
2016.10
PIC/S GMP
Misoprostol Tablets and Mifepristone （200mg）Tablets
2016.09
2016.09
Mexico COFEPRIS
Misoprostol Tablets
2016.01
2016.01
WHO GMP
Misoprostol Tablets and Mifepristone （200mg）Tablets
2013.09
2013.09
Mexico COFEPRIS
Levonorgestrel,Mifepristone,Ethinyl Estradiol API
2012.05
2012.05
WHO GMP
Levonorgestrel,Mifepristone,Ethinyl Estradiol API